chemotherapy-induced peripheral neuropathy
Conditions
Interventions
Lafutidine is administered orally at the dose of 10 mg twice daily for 8 weeks.
Mecobalamin is administered orally at the dose of 500 microgram three times daily for 8 weeks.
Sponsors
Department of breast and endocrine surgery, Meiwa Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)Breast cancer patient with taxane-induced peripheral neuropathy, which continued more than 1 month after chemotherapy with taxane (paclitaxel, nab-paclitaxel, docetaxel). 2)with residual peripheral neuropathy in spite of goshajinkigan administered 3)with digestive symptom such as upper abdominal discomfort 4)written informed consent
Exclusion criteria
Exclusion criteria: 1)not goshajinkigan administered 2)with severe complications (such as liver failure, renal failure, heart failure) 3)with history of allergy 4)alredy adminstered with Goshajinkigan, Mecobalamin or Lafutidine. 5)with peripheral neuropathy for other cause (such as diabetes) 6)receiving drugs to influence peripheral neuropathy 7)doctore's decision not to be registered to this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The level of improvement of peripheral neuropathy is evaluated by Visual Analogue Scale (VAS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety | — |
Countries
Japan
Contacts
Public ContactMasahiro Kishimoto
Meiwa Hospital Department of breast and endocrine surgery
Outcome results
None listed